Literature DB >> 27339497

The Diagnosis and Evaluation of Dilated Cardiomyopathy.

Alan G Japp1, Ankur Gulati2, Stuart A Cook3, Martin R Cowie4, Sanjay K Prasad4.   

Abstract

Dilated cardiomyopathy (DCM) is best understood as the final common response of myocardium to diverse genetic and environmental insults. A rigorous work-up can exclude alternative causes of left ventricular (LV) dilation and dysfunction, identify etiologies that may respond to specific treatments, and guide family screening. A significant proportion of DCM cases have an underlying genetic or inflammatory basis. Measurement of LV size and ejection fraction remain central to diagnosis, risk stratification, and treatment, but other aspects of cardiac remodeling inform prognosis and carry therapeutic implications. Assessment of myocardial fibrosis predicts both risk of sudden cardiac death and likelihood of LV functional recovery, and has significant potential to guide patient selection for cardioverter-defibrillator implantation. Detailed mitral valve assessment is likely to assume increasing importance with the emergence of percutaneous interventions for functional mitral regurgitation. Detection of pre-clinical DCM could substantially reduce morbidity and mortality by allowing early instigation of cardioprotective therapy.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  imaging; implantable cardioverter-defibrillator; remodeling

Mesh:

Year:  2016        PMID: 27339497     DOI: 10.1016/j.jacc.2016.03.590

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  98 in total

Review 1.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms.

Authors:  Elizabeth M McNally; Luisa Mestroni
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

2.  Specifics of fetuin-A levels in distinct types of chronic heart failure.

Authors:  Michael Lichtenauer; Bernhard Wernly; Vera Paar; Ilonka Rohm; Christian Jung; Atilla Yilmaz; Uta C Hoppe; Paul Christian Schulze; Daniel Kretzschmar; Rudin Pistulli
Journal:  J Clin Lab Anal       Date:  2017-02-18       Impact factor: 2.352

3.  Left Ventricular Dilation: When Pediatric Meet Adult Guidelines.

Authors:  Jill Harmon; Kacy Sisco; Marc Dutro; Clifford L Cua
Journal:  Pediatr Cardiol       Date:  2017-09-07       Impact factor: 1.655

4.  Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study.

Authors:  Daniel D Kinnamon; Ana Morales; Deborah J Bowen; Wylie Burke; Ray E Hershberger
Journal:  Circ Cardiovasc Genet       Date:  2017-12

5.  Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.

Authors:  Wanjian Tang; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

6.  Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations.

Authors:  Fernando Domínguez; Sofía Cuenca; Zofia Bilińska; Rocío Toro; Eric Villard; Roberto Barriales-Villa; Juan Pablo Ochoa; Folkert Asselbergs; Arjan Sammani; Maria Franaszczyk; Mohammed Akhtar; Maria José Coronado-Albi; Diego Rangel-Sousa; Jose F Rodriguez-Palomares; Juan Jiménez-Jáimez; José Manuel Garcia-Pinilla; Tomás Ripoll-Vera; Maria Victoria Mogollón-Jiménez; Ana Fontalba-Romero; Dolores Garcia-Medina; Julian Palomino-Doza; David de Gonzalo-Calvo; Marcos Cicerchia; Joel Salazar-Mendiguchia; Clara Salas; Sabine Pankuweit; Thomas Morris Hey; Jens Mogensen; Paul J Barton; Philippe Charron; Perry Elliott; Pablo Garcia-Pavia
Journal:  J Am Coll Cardiol       Date:  2018-11-13       Impact factor: 24.094

Review 7.  Genetics of dilated cardiomyopathy: practical implications for heart failure management.

Authors:  Andrew N Rosenbaum; Katherine E Agre; Naveen L Pereira
Journal:  Nat Rev Cardiol       Date:  2019-10-11       Impact factor: 32.419

8.  Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy.

Authors:  Keisuke Inui; Kuniya Asai; Masaki Tachi; Aya Yoshinaga; Yuki Izumi; Yoshiaki Kubota; Koji Murai; Yayoi Tetsuou Tsukada; Yasuo Amano; Shinichiro Kumita; Wataru Shimizu
Journal:  Heart Vessels       Date:  2018-03-20       Impact factor: 2.037

9.  CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling.

Authors:  Sung Wook Park; Shawna D Persaud; Stanislas Ogokeh; Tatyana A Meyers; DeWayne Townsend; Li-Na Wei
Journal:  J Endocrinol       Date:  2018-01-25       Impact factor: 4.286

10.  Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p.

Authors:  Chunping Zhu; Haijun Zhang; Dongmei Wei; Zhe Sun
Journal:  Acta Diabetol       Date:  2021-06-06       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.